Blueprint Medicines to Report Updated Data from the Phase 2 PIONEER Trial of Avapritinib in Indolent Systemic Mastocytosis on Monday, March 16, 2020 Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer...

Blueprint Medicines previously announced plans to present a late-breaking oral abstract on the PIONEER trial data at the 2020 AAAAI Annual Meeting. Due to the cancellation of the AAAAI Annual Meeting, Blueprint Medicines now plans to report the data during the investor conference call and webcast on March 16, 2020 at 7:30 a.m. ET .

Conference Call Information

To access the live call, please dial (855) 728-4793 (domestic) or (503) 343-6666 (international) and refer to conference ID 1590639. A webcast of the conference call will be available in the Investors & Media section of Blueprint Medicines' website at http://ir.blueprintmedicines.com . The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call.

About Blueprint Medicines

SOURCE Blueprint Medicines Corporation